Lilly(US:LLY) 智通财经网·2025-05-01 13:03Group 1 - Company Eli Lilly (LLY.US) reported Q1 2025 earnings with revenue of $12.73 billion, slightly exceeding market expectations of $12.67 billion [1] - Adjusted EPS for the quarter was $3.34, significantly higher than Wall Street's expectation of $3.10 [1] - The company lowered its full-year adjusted EPS guidance to a range of $20.78 to $22.28, down from the previous guidance of $22.50 to $24 [1] Group 2 - Core products performed as expected, with the weight loss drug Zepbound generating $2.31 billion in sales, in line with analyst expectations [2] - Diabetes drug Mounjaro achieved $3.84 billion in revenue, slightly above the analyst forecast of $3.77 billion [2] - The company faces competitive pressure as CVS Health announced a reduction in Novo Nordisk's weight loss drug procurement prices, potentially impacting Eli Lilly's market share [2]